The utility of the proliferative index in pretreatment biopsy specimens of esophageal squamous cell carcinoma

Diseases of the Esophagus

Volumn 11, Issue 4, 1998, Pages 215-220

  Zhang, X D ^a   Coventry, B J ^a   Jamieson, G G ^a   Gill, P G ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; MONOCLONAL ANTIBODY KI 67;

ADULT; AGED; ARTICLE; BIOPSY; CANCER STAGING; CELL PROLIFERATION; CLINICAL ARTICLE; ENDOSCOPY; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LYMPH NODE METASTASIS; MALE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; SURVIVAL RATE; TUMOR DIFFERENTIATION;

EID: 0032467865     PISSN: 11208694     EISSN: None     Source Type: Journal    
DOI: 10.1093/dote/11.4.215     Document Type: Article

References (14)

1. Fink U, Stein H J, Wilke H et al. Multimodal treatment for squamous cell esophageal cancer. World J Surg 1995; 19: 198-204.
2. Burmeister B H, Denham J W, O' Brien M et al. Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study. Int J Radiat Oncol Biol Phys 1995; 32: 997-1006.
3. Bates B A, Detterbeck F C, Bernard S A et al. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma J Clin Oncol 1996; 14: 156-163.
4. Bessell J R, Devitt P G, Gill P G et al. Prolonged survival follows resection of oesophageal SCC downstaged by prior chemoradiotherapy. Aust N Z J Surg 1996; 66: 214-217.
5. Smithers B M, Devitt P, Jamieson G G et al. A combined modality approach to the management of oesophageal cancer. Eur J Surg Oncol 1997; 23: 219-223.
6. Coia L R, Engstrom P F, Paul A. Nonsurgical management of esophageal cancer: report of a study of combined radiotherapy and chemotherapy. J Clin Oncol 1987; 5: 1783-1790.
7. Gill P G, Denham J W, Jamieson G G et al. Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery. J Clin Oncol 1992; 10: 1037-1043.
8. Hickey K, Grehan D, Reid I M et al. Expression of epidermal grow th factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer 1994; 74: 1693-1698.
9. Yu C C, Woods A L, Levison D A. The assessment of cellular proliferation by immunohistochemistry: a review of currently available methods and their applications. Histochem J 1992; 24: 121-131.
10. Yu C C, Filipe M I. Update on proliferation-associated antibodies applicable to formalin-fixed paraffin-embedded tissue and their clinical applications. Histochem J 1993; 25: 843-853.
11. Cattoretti G, Becker M H, Key G et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168: 357-363.
12. Lam K Y, Law S Y, So M K. et al. Prognostic implication of proliferative markers MIB-1 and PC10 in esophageal squamous cell carcinoma. Cancer 1996; 77: 7-13.
13. Youssef E M, Matsuda T, Takada N et al. Prognostic significance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the esophagus. Cancer 1995; 76: 358-366.
14. Finder S E, Wencyk P, Sibbering D M et al. Assessment of the new proliferation marker MIB 1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 1995; 71: 146-149.